Evommune reports Q1 net loss $21.7M; EVO756 Phase 2b data due June 2026 in CSU

Evommune, Inc.

2026-Q1 EPS reported -$0.64

Net loss $21.7M in Q1 2026 vs $14.6M prior year; cash, equivalents and investments $307.0M as of March 31, 2026.
EVO756 Phase 2b top-line data in chronic spontaneous urticaria expected June 2026; atopic dermatitis data in Q3 2026.
Phase 2b dose-ranging trial for EVO756 in migraine prophylaxis to start mid-2026; top-line data anticipated in 2027.
EVO301 Phase 2b atopic dermatitis trial planned for mid-2027 after positive Phase 2a proof-of-concept data in February 2026.
Revenue zero vs $3.0M prior year (Maruho collaboration ended); R&D expenses $17.3M, G&A $6.6M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evommune, Inc. reported first quarter ended March 31, 2026 results: revenue zero.

Period: first quarter ended March 31, 2026
Revenue: zero
Result: reported results

Exact text from the filing

Revenue was zero for the first quarter ended March 31, 2026, compared to $3.0 million for the same period in 2025, attributable to the Company’s strategic collaboration with Maruho related to licensing EVO756 in Japan.

View on SEC.gov

Browse all earnings releases →

Evommune, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211934

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.